human
immunodefici
viru
hiv
pandem
drive
reemerg
tuberculosi
tb
global
health
threat
increas
suscept
hivinfect
peopl
infect
mycobacterium
tuberculosi
mtb
increas
rate
emerg
drugresist
mtb
sever
clinic
challeng
treatment
coinfect
patient
includ
expens
pill
burden
toxic
malabsorpt
necessit
search
new
drug
may
effect
pathogen
simultan
antihelminth
niclosamid
shown
activ
laboratori
strain
mtb
liquid
cultur
bacteriostat
activ
nonrepl
abscessu
also
recent
describ
extend
find
demonstr
niclosamid
inhibit
mycobacteri
growth
infect
human
macrophag
mediat
potent
bacteriostat
activ
virul
mtb
beij
strain
importantli
provid
first
evid
niclosamid
inhibit
hiv
replic
human
macrophag
jurkat
cell
postintegr
effect
proviru
transcript
dual
antivir
antimycobacteri
activ
observ
vitro
model
hiv
mtb
coinfect
use
human
primari
monocytederiv
macrophag
result
support
investig
niclosamid
deriv
antiretroviralantimycobacteri
agent
may
reduc
clinic
challeng
associ
multidrug
regimen
drug
resist
tuberculosi
reemerg
global
health
threat
larg
driven
hiv
pandem
accord
global
tuberculosi
report
million
new
tb
infect
approxim
million
tb
relat
death
tb
lead
caus
infecti
diseas
relat
death
worldwid
well
lead
caus
death
peopl
live
hiv
plwh
hiv
infect
increas
suscept
new
infect
reinfect
mtb
increas
risk
latent
tuberculosi
infect
ltbi
reactiv
greater
new
tb
infect
global
occur
plwh
mani
subsaharan
african
countri
new
recur
tb
case
observ
plwh
exacerb
problem
emerg
drug
resist
mtb
nearli
half
million
peopl
identifi
multi
mdr
extrem
drug
resist
xdr
strain
mtb
compound
problem
incid
drug
resist
mtb
higher
plwh
without
hiv
chanc
tbrelat
mortal
greater
addit
simultan
treatment
tb
hiv
proven
difficult
mani
frontlin
hiv
drug
perform
poorli
use
combin
frontlin
tb
drug
particularli
rifampicin
hiv
like
mtb
also
experienc
emerg
resist
antiretrovir
high
mutat
rate
associ
retrovir
revers
transcriptas
result
rapid
develop
drug
resist
viral
speci
partial
overcom
combin
therapi
combin
factor
necessit
constant
search
new
therapeut
treat
one
pathogen
without
signific
side
effect
interact
toxic
also
obviat
http
accept
decemb
opportun
revisit
nonfirst
line
drug
resist
yet
emerg
effect
perhap
even
dualact
deriv
may
synthes
niclosamid
antihelminth
drug
introduc
use
treat
parasit
infect
million
patient
worldwid
shown
effect
number
host
cellular
signal
pathway
includ
wnt
notch
mtor
broad
activ
led
evalu
therapeut
agent
number
cancer
includ
breast
colon
ovarian
prostat
other
also
shown
potenti
treat
bacteri
viral
infect
bacillu
anthraci
pseudomona
aeruginosa
staphylococcu
aureu
well
sarscov
influenza
chikungunya
zika
virus
addit
niclosamid
investig
potenti
antimycobacteri
drug
sun
et
al
show
niclosamid
could
inhibit
growth
mtb
laboratori
strain
low
micromolar
concentr
liquid
cultur
berub
et
al
recent
demonstr
activ
abscessu
nonrepl
model
investig
activ
niclosamid
virul
beij
strain
mtb
set
mycobacteria
hiv
coinfect
human
macrophag
observ
niclosamid
reduc
growth
mtb
beij
well
bovi
bacillu
bcg
vaccin
strain
liquid
cultur
interest
identifi
potent
antivir
activ
niclosamid
hiv
human
macrophag
well
cell
support
potenti
therapeut
applic
simultan
activ
hiv
mycobacteria
coinfect
human
macrophag
observ
find
indic
inhibit
hiv
replic
occur
postintegr
via
effect
proviru
transcript
result
support
investig
niclosamid
therapeut
mix
infect
includ
mtb
hiv
jrcsf
obtain
ucla
center
aid
research
follow
reagent
obtain
nih
aid
reagent
program
divis
aid
niaid
nih
infect
cell
dr
thoma
folk
follow
reagent
obtain
nih
aid
reagent
program
divis
aid
niaid
nih
jlat
full
length
cell
dr
eric
verdin
cat
jlat
cell
jurkat
cell
line
infect
hiv
gfp
express
gfp
hiv
provir
transcript
occur
buffi
coat
use
isol
monocyt
cultur
monocytederiv
macrophag
mdm
purchas
gulf
coast
blood
center
houston
tx
mycobacteria
tuberculosi
beij
kind
gift
dr
michel
larsen
albert
einstein
colleg
medicin
mycobacterium
bovi
bcg
obtain
atcc
atcc
bovi
bcg
pasteurtdtomato
develop
dr
jeffrey
cirillo
texa
health
scienc
center
liquid
cultur
bovi
bcg
pasteur
mtb
beij
grown
od
dilut
od
media
drug
ad
indic
cultur
assess
baselin
od
read
specif
compound
grown
addit
seven
day
aerob
condit
shaken
daili
experi
perform
use
mtb
conduct
biosafeti
level
facil
galveston
nation
laboratori
complex
deidentifi
buffi
coat
sampl
store
room
temperatur
day
transport
utmb
campu
gulf
coast
blood
center
use
isol
peripher
blood
mononuclear
cell
pbmc
peripher
blood
monocyt
isol
pbmc
overnight
adher
ml
tissu
cultur
flask
describ
monocyt
dissoci
gibco
dissoci
media
count
hemacytomet
use
trypan
blue
assess
viabil
monocyt
subsequ
dispens
well
tissu
cultur
plate
cell
per
well
respect
use
gener
monocyt
deriv
macrophag
mdm
cultur
day
ngml
mcsf
peprotech
media
chang
day
mdm
infect
tcid
jrcsf
minim
media
overnight
cell
subsequ
wash
pb
media
replac
cell
mdm
infect
mycobacteria
tuberculosi
beij
moi
mycobacterium
bovi
bcg
moi
h
antibioticfre
media
previous
describ
cell
wash
media
contain
penstrep
media
replac
complet
cell
incub
co
h
cell
lyse
commerci
lysi
buffer
pierc
contain
proteas
inhibitor
dnase
protein
concentr
determin
use
bca
kit
pierc
protein
load
per
well
separ
acrylamid
gel
biorad
transfer
pvdf
pvdf
membran
coomassi
blue
stain
antibodi
probe
ensur
equal
load
membran
probe
hrpconjug
antibodi
abcam
visual
bioluminesc
supersign
west
femto
substrat
thermofish
expos
xray
film
develop
rna
isol
use
quickrna
kit
zymo
treat
dnase
cdna
synthes
iscript
cdna
kit
biorad
semiquantit
rtpcr
perform
detect
hiv
ltr
previous
describ
use
itaq
sybr
green
master
mix
biorad
lightcycl
instrument
biorad
normal
gapdh
housekeep
gene
cell
harvest
appropri
time
point
wash
pb
prior
incub
fixabl
livedead
aqua
invitrogen
per
manufactur
instruct
cell
fix
permeabil
bd
cytoffixcytoperm
solut
becton
dickinson
intracellular
stain
fixat
permeabil
cell
stain
intracellular
hiv
beckman
coulter
rins
three
time
fix
ultrapur
formaldehyd
pb
sampl
acquir
use
bd
lsr
ii
fortessa
data
analyz
use
flowjo
denovo
previous
demonstr
niclosamid
inhibit
growth
liquid
cultur
order
determin
activ
virul
clinic
isol
mycobacteria
incub
liquid
cultur
bovi
bcg
control
mtb
beij
presenc
media
alon
common
antimycobacteri
drug
rifampicin
rif
isoniazid
inh
nm
increas
concentr
niclosamid
fig
agreement
data
order
assess
potenti
niclosamid
act
antiretrovir
well
antimycobacteri
examin
effect
hiv
replic
cycl
given
niclosamid
known
mechan
action
suppress
host
signal
pathway
led
hiv
replic
hypothes
might
interrupt
hiv
replic
postintegr
phase
viral
life
cycl
test
hypothesi
activ
cell
human
macrophag
cell
line
integr
genom
presenc
increas
concentr
niclosamid
media
alon
cell
harvest
stain
near
livedead
marker
mab
evalu
flow
cytometri
fig
percent
cell
posit
hiv
observ
decreas
dose
depend
manner
fig
effect
seen
absenc
measur
toxic
concentr
examin
fig
knowledg
first
demonstr
capac
niclosamid
act
antiretrovir
agent
open
door
investig
niclosamid
deriv
potenti
dualact
drug
patient
coinfect
hiv
mtb
complex
infect
import
observ
mtb
infect
known
activ
pathway
welldefin
role
initi
hiv
replic
infect
cell
niclosamid
directli
bacteriostat
hostdirect
effect
indirectli
oppos
hiv
replic
explor
mechan
niclosamid
inhibit
hiv
replic
assay
activ
cell
total
hiv
western
blot
hiv
transcript
encod
gag
pol
transcrib
translat
singl
polypeptid
thu
presenc
absenc
good
indic
statu
de
novo
synthesi
hiv
protein
seen
fig
cell
activ
presenc
niclosamid
nearli
absent
determin
result
silenc
hiv
transcript
disrupt
posttranscript
process
assay
cell
activ
condit
presenc
hiv
transcript
semiquantit
rtpcr
hiv
long
termin
repeat
ltr
fold
chang
hiv
transcript
detect
rtpcr
cell
activ
presenc
niclosamid
significantli
lower
activ
media
alon
nearli
level
nonactiv
cell
fig
find
indic
niclosamid
like
act
partial
inhibitor
transcript
integr
hiv
provir
genom
import
date
antiretrovir
drug
disrupt
everi
stage
viral
life
cycl
entri
revers
transcript
integr
particl
matur
provir
transcript
yet
target
therapeut
also
possibl
niclosamid
act
way
affect
level
provir
transcript
nuclear
entrap
increas
degrad
viral
rna
addit
studi
need
differenti
possibl
mechan
explor
niclosamid
deriv
may
potenti
lead
new
class
antiretrovir
drug
gener
well
new
approach
complement
tb
chemotherapi
cell
rather
macrophag
primari
host
hiv
infect
propos
verifi
niclosamid
activ
inhibit
viral
replic
cell
end
activ
jlat
cell
cell
line
integr
recombin
hivgfp
genom
presenc
increas
concentr
niclosamid
use
approach
cell
discern
cell
niclosamid
decreas
percent
hiv
jlat
cell
dose
depend
manner
fig
greater
cell
death
observ
absenc
well
increas
concentr
drug
seen
jlat
vs
cell
fig
howev
activ
assess
live
gate
demonstr
potent
antiretrovir
activ
human
cell
fig
result
demonstr
potenti
niclosamid
inhibit
replic
import
hiv
target
cell
macrophag
given
central
role
cell
mediat
immun
host
contain
mtb
result
suggest
potenti
niclosamid
spare
effect
immun
mechan
key
protect
tb
determin
niclosamid
could
effect
primari
cell
relev
coinfect
model
employ
vitro
coinfect
system
mdm
infect
hiv
jrcsf
bovi
bcg
express
fluorochrom
tdtomato
presenc
absenc
niclosamid
assay
hiv
protein
product
mycobacteria
via
flow
cytometri
fig
show
niclosamid
treatment
result
greater
decreas
hiv
protein
mycobacteria
coinfect
macrophag
absenc
signific
cell
death
due
drug
toxic
result
support
potenti
therapeut
applic
niclosamid
similar
compound
complex
coinfect
hiv
popul
work
expand
known
activ
niclosamid
mycobacteria
includ
import
virul
clinic
isol
mtb
result
indic
drug
could
potenti
repurpos
combat
tb
infect
current
era
emerg
drug
resist
provid
first
evid
knowledg
potent
antiretrovir
activ
niclosamid
hiv
present
excit
possibl
one
drug
may
activ
hiv
mtb
simultan
potenti
facilit
treatment
condit
singl
drug
coinfect
scenario
would
reduc
challeng
advers
drug
interact
encount
tri
treat
patient
common
deadli
coinfect
also
rais
possibl
new
drug
treatment
either
infect
resist
yet
arisen
either
pathogen
believ
data
present
herein
justifi
examin
niclosamid
novel
deriv
dualact
agent
hivtb
coinfect
studi
support
institut
human
infect
immun
depart
microbiolog
immunolog
univers
texa
medic
branch
galveston
tx
none
declar
macrophag
cultur
presenc
absenc
niclosamid
day
cell
harvest
stain
livedead
marker
fix
permeabil
stain
antibodi
analyz
flow
cytometri
niclosamid
reduc
replic
pathogen
without
signific
cell
loss
due
drug
toxic
data
shown
repres
three
separ
experi
similar
result
applic
public
supplement
support
univers
texa
health
scienc
center
houston
